| Autor: |
MINEHIKO INOMATA, YOSUKE KAWASHIMA, RYOTA SAITO, DAISUKE MORINAGA, HITOMI NOGAWA, MASAMICHI SATO, YOHEI SUZUKI, SATORU YANAGISAWA, TAKASHI KIKUCHI, DAISUKE JINGU, NARUO YOSHIMURA, TOSHIYUKI HARADA, EISAKU MIYAUCHI |
| Předmět: |
|
| Zdroj: |
Cancer Diagnosis & Prognosis; Jul/Aug2024, Vol. 4 Issue 4, p515-520, 6p |
| Abstrakt: |
Background/Aim: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective for treating non-small cell lung cancer (NSCLC) harboring EGFR mutations. However, higher tumor programmed death ligand-1 (PD-L1) expression is associated with a poor response to EGFR-TKIs, and information on the comparison between afatinib and osimertinib in PD-L1-positive EGFR-mutant NSCLC is scarce. Patients and Methods: We retrospectively analyzed data of patients with PD-L1-positive EGFR-mutant NSCLC to compare the effectiveness of afatinib and osimertinib. Results: A total of 177 patients were included in the study. The Cox proportion hazard model was adjusted for age, sex, performance status, EGFR mutation status, PD-L1 expression level, and brain metastasis, revealing that there was no significant difference in risk for progression [hazard ratio (HR)=0.99, 95% confidence interval (CI)=0.64-1.53] or death (HR=0.96, 95% CI=0.54-1.73) between afatinib and osimertinib. Conclusion: In conclusion, the EGFR-TKI treatment duration and overall survival after the treatment with afatinib or osimertinib were similar in patients with PD-L1- positive EGFR-mutant NSCLC in the present study. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
